farnesol has been researched along with salicylates in 157 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (8.28) | 18.2507 |
| 2000's | 58 (36.94) | 29.6817 |
| 2010's | 80 (50.96) | 24.3611 |
| 2020's | 6 (3.82) | 2.80 |
| Authors | Studies |
|---|---|
| Ben-Baruch, G; Egozi, Y; Haklai, R; Kloog, Y; Marciano, D; Marom, M | 2 |
| Aviram, I; Halpern, M; Kloog, Y; Marciano, D; Tisch, D | 1 |
| Ben-Baruch, G; Egozi, Y; Gana-Weisz, M; Haklai, R; Kloog, Y; Marciano, D | 1 |
| Ben-Baruch, G; Egozi, Y; Elad, G; Haklai, R; Kloog, Y; Marciano, D; Paz, A; Weisz, MG | 1 |
| Aharonson, Z; Gana-Weisz, M; Haklai, R; Kloog, Y; Marciano, D; Varsano, T | 1 |
| Gutman, O; Henis, YI; Kloog, Y; Niv, H | 1 |
| Ben-Baruch, G; Egozi, Y; Gana-Weisz, M; Kloog, Y; Weisz, B | 1 |
| Ben-Baruch, G; Egozi, Y; Gana-Weisz, M; Giehl, K; Gierschik, P; Kloog, Y; Marciano, D; Weisz, B | 1 |
| Ben-David, E; Eichler, H; Gana-Weisz, M; Heere-Ress, E; Jansen, B; Kahr, H; Kloog, Y; Mayer, BX; Pehamberger, H; Schlagbauer-Wadl, H; Wolff, K | 1 |
| Cox, A; Elad, G; Haklai, R; Kloog, Y; Marciano, D; Paz, A | 1 |
| Aeed, H; Avni, Y; Bruck, R; Gana-Weis, M; Kloog, Y; Pinzani, M; Reif, S; Romanelli, RG; Weis, B; Zaidel, L | 1 |
| Halaschek-Wiener, J; Heere-Ress, E; Jansen, B; Kloog, Y; Marciano, D; Moll, I; Pehamberger, H; Schlagbauer-Wadl, H; Waltering, S; Wolff, K | 1 |
| Cox, AD; Kloog, Y | 1 |
| Halaschek-Wiener, J; Jansen, B; Kloog, Y; Schlagbauer-Wadl, H; Wacheck, V; Wolff, K | 1 |
| Barzilai, A; Daily, D; Holmgren, A; Melamed, E; Mittelman, L; Offen, D; Vlamis-Gardikas, A | 1 |
| Abramsky, O; Chapman, J; Grigoriadis, N; Karussis, D; Kloog, Y; Mizrachi-Koll, R; Niv, H | 1 |
| Blank, M; Chapman, J; Karussis, DM; Katzav, A; Kloog, Y; Korczyn, AD; Niv, H; Rabinowitz, R; Shoenfeld, Y; Wang, N | 1 |
| Elad, G; Gana-Weisz, M; Haklai, R; Halaschek-Wiener, J; Jansen, B; Kloog, Y | 1 |
| Eisen, TG; Smalley, KS | 2 |
| Afek, A; George, J; Goldberg, I; Haklai, R; Herz, I; Keren, G; Keren, P; Kloog, Y | 1 |
| Halaschek-Wiener, J; Jansen, B; Kloog, Y; Wacheck, V | 1 |
| Blank, M; Chapman, J; Katzav, A; Kloog, Y; Korczyn, AD; Molina, V; Shoenfeld, Y | 1 |
| Clarke, HC; Cook, HT; Hendry, BM; Khwaja, A; Kloog, Y; Kocher, HM | 1 |
| Berstein, LM; Harada, H; Lykkesfeldt, AE; Naftolin, F; Santen, RJ; Shanabrough, M; Wang, JP; Yue, W; Zheng, H | 1 |
| Alexandrovich, A; Biegon, A; Elad-Sfadia, G; Grossman, R; Haklai, R; Kloog, Y; Shohami, E; Yatsiv, I | 1 |
| Dietrich, A; Gierschik, P; Henis, YI; Illenberger, D; Kloog, Y; Scheer, A | 1 |
| Cox, AD; Kloog, Y; Lindenboim, L; Shalom-Feuerstein, R; Stein, R | 1 |
| Barshack, I; Elad-Sfadia, G; George, J; Goldberg, I; Haklai, R; Keren, G; Keren, P; Kloog, Y; Sack, J | 1 |
| Conaway, MC; Gregory, CW; McPherson, RA; Santen, RJ; Yue, W | 1 |
| Aquino Duarte, FA; Couto, AS; Katzin, AM; Kimura, EA; Peres, VJ; Rodrigues Goulart, H | 1 |
| Bottiglieri, T; Chin, PC; D'Mello, SR; Liu, L; Morrison, BE; Ratan, RR; Siddiq, A | 1 |
| Aeed, H; Bruck, R; Kloog, Y; Kweon, YO; Reich, R; Reif, S; Shilo, Y | 1 |
| Lawrence, JC; McMahon, LP; Santen, RJ; Yue, W | 1 |
| Savage, CO; Williams, JM | 1 |
| Amariglio, N; Blum, R; Jacob-Hirsch, J; Kloog, Y; Rechavi, G | 1 |
| Fan, P; Li, Y; Santen, RJ; Wang, J; Yue, W | 1 |
| Bachireddy, P; Bendapudi, PK; Felsher, DW | 1 |
| Amariglio, N; Haklai, R; Jacob-Hirsch, J; Kloog, Y; Rechavi, G; Yaari, S | 1 |
| Hendry, BM; Khwaja, A; Kloog, Y; Noor, M; Sharpe, CC | 1 |
| Chapman, J; Drory, V; Ferdman-Aronovich, R; Kafri, M; Katzav, A; Kloog, Y; Korczyn, AD; Wirguin, I | 1 |
| Amos, S; Hussaini, IM; McPheson, R; Polar, G; Redpath, GT; Schiff, D | 1 |
| Lynch, AR; McPherson, RA; Neal, LR; Santen, RJ; Yue, W | 1 |
| Aronovich, R; Chapman, J; Gurwitz, D; Kloog, Y | 1 |
| Maren, S; Merino, SM | 1 |
| Blum, R; Elkon, R; Goldberg, L; Kloog, Y; Nakdimon, I; Rechavi, G; Shamir, R | 1 |
| Berzat, AC; Brady, DC; Cox, AD; Fiordalisi, JJ | 1 |
| Blum, R; Erlich, S; Karunagaran, D; Kloog, Y; Liebling, R; Pinkas-Kramarski, R; Tal-Or, P | 1 |
| Blum, R; Jacob-Hirsch, J; Kloog, Y; Rechavi, G | 1 |
| Barkan, B; Friedman, E; Kloog, Y; Starinsky, S; Stein, R | 1 |
| Barkan, B; Fridman, E; Friedman, E; Kloog, Y; Shapira, S; Stein, R | 1 |
| Akçit, F; Cağlar, S; Cetin, A; Ozturk, OH; Tokay, A; Yeşilkaya, A | 1 |
| Blum, R; Elkon, R; Jacob-Hirsch, J; Kloog, Y; Rechavi, G; Shamir, R; Yaari, S; Zundelevich, A | 1 |
| Elad-Sfadia, G; Haklai, R; Kloog, Y; Zundelevich, A | 1 |
| da Silva Morais, A; Horsmans, Y; Leclercq, I; Saliez, A; Stärkel, P | 1 |
| Hill, RP; Zhang, L | 1 |
| Alexandrovitch, A; Brandeis, R; Goelman, G; Kloog, Y; Marciano, D; Shohami, E | 1 |
| Egozi, Y; Elad-Sfadia, G; Haklai, R; Kloog, Y | 1 |
| Bar-Zohar, D; Kloog, Y; Oren, R; Reif, S; Zvibel, I | 1 |
| Ao, H; Banke, T; Breitenbucher, JG; Chaplan, SR; Maher, M; Nasser, N; Wickenden, AD; Wu, NT | 1 |
| Blum, R; Cox, AD; Kloog, Y | 1 |
| Ehrlich, M; Haklai, R; Kloog, Y; Rotblat, B | 1 |
| George, J; Keren, G; Kloog, Y; Mor, A | 2 |
| He, P; Hidalgo, M; Laheru, D; Rudek, MA; Xu, L; Zhao, M | 1 |
| Cohen, ZR; Daniels, D; Goldberg, L; Kloog, Y; Last, D; Mardor, Y; Ocherashvilli, A; Tamar, G | 1 |
| Bauer, V; Goldberg, L; Haklai, R; Heiss, A; Kloog, Y | 1 |
| Cheporko, Y; George, J; Haklai, R; Hochhauser, E; Keren, G; Kloog, Y; Maysel-Auslender, S; Pando, R; Porat, E; Sagie, A | 1 |
| Abarca, J; Borbath, I; Charette, N; De Saeger, C; Horsmans, Y; Leclercq, I; Schneider-Merck, T; Stärkel, P | 2 |
| Blair, J; Goldsweig, H; Hong, D; Kurzrock, R; Ng, CS; Rudek, MA; Tsimberidou, AM | 1 |
| Kloog, Y; Kraitzer, A; Zilberman, M | 1 |
| Cox, AD; Der, CJ; Hanker, AB; Henske, EP; Mitin, N; Tamanoi, F; Wilder, RS | 1 |
| Jacob-Hircsh, J; Kloog, Y; Nevo-Caspi, Y; Rechavi, G; Shaked, M; Shamir, R; Yaari-Stark, S | 1 |
| Ji, H; Lai, Y; Ling, Y; Peng, S; Tian, J; Ye, X; Zhang, Y | 1 |
| Banke, TG; Chaplan, SR; Wickenden, AD | 1 |
| Biran, A; Brownstein, M; Haklai, R; Kloog, Y | 1 |
| Bustinza-Linares, E; Kurzrock, R; Tsimberidou, AM | 1 |
| Chang, SG; Cho, JM; Choi, KJ; Choi, TG; Ha, J; Hong, F; Kim, SS; Kim, YJ; Lee, J; Lee, S; Lim, MJ; Tak, E | 1 |
| Haklai, R; Kloog, Y; Kraitzer, A; Zilberman, M | 1 |
| Grafi-Cohen, M; Kloog, Y; Kraiem, Z; Levy, R | 1 |
| Ben-Moshe, O; Kloog, Y; Mekori, YA; Mor, A | 1 |
| Charette, N; De Saeger, C; Horsmans, Y; Lannoy, V; Leclercq, I; Stärkel, P | 1 |
| Aizman, E; Assaf, Y; Chapman, J; Kloog, Y; Mor, A | 1 |
| Bhagatji, P; Leventis, R; Lin, CJ; Rich, R; Silvius, JR | 1 |
| Aga-Mizrachi, S; Brunschwig, Z; Chapman, J; Dadush, O; Elad-Sfadia, G; Elbaz, M; Elmakayes, E; Ettinger, K; Haklai, R; Kloog, Y; Nevo, Y; Reif, S; Yanay, N | 1 |
| Haklai, R; Kloog, Y; Makovski, V | 1 |
| Ji, H; Lai, Y; Ling, Y; Peng, S; Tian, J; Ye, X; Zhang, Y; Zhang, Z | 1 |
| Borbath, I; Stärkel, P | 1 |
| Ji, H; Ling, Y; Tang, J; Yang, L; Zhang, Y; Zhang, Z; Zhao, Q | 1 |
| Barkan, B; Ehrlich, M; Kloog, Y | 1 |
| Ben-Moshe, O; Haklai, R; Kloog, Y; Mekori, YA; Mor, A | 1 |
| Aizman, E; George, J; Kloog, Y; Mor, A | 1 |
| Azzoli, CG; Ginsberg, MS; Johnson, ML; Kris, MG; Krug, LM; Medina, C; Miller, VA; Pao, W; Pietanza, MC; Riely, GJ; Rizvi, NA | 1 |
| Aizman, E; Brazowski, E; Elad-Sfadia, G; Haklai, R; Kloog, Y; Oron, T; Reif, S | 1 |
| Aizman, E; George, J; Kloog, Y; Levy, A; Mor, A | 1 |
| Jaggi, AS; Singh, N | 1 |
| Goldberg, L; Israeli, R; Kloog, Y | 1 |
| András, IE; Eum, SY; Toborek, M | 1 |
| Donehower, R; Goldsweig, H; Hidalgo, M; Jimeno, A; Laheru, D; Le, DT; Linden, S; McAllister, F; Rajeshkumar, NV; Rudek, MA; Shah, P; Song, D; Taylor, G; Zhao, M | 1 |
| Aizman, E; Kloog, Y; Mor, A | 1 |
| Carmeli, S; Elad-Sfadia, G; Haklai, R; Kloog, Y; Mashiach-Farkash, E; Rak, R; Wolfson, HJ | 1 |
| Alperstein, D; Kloog, Y; Kraitzer, A; Zilberman, M | 1 |
| Brussolo, S; Ceccon, M; Gambacorti-Passerini, C; Mologni, L | 1 |
| Charette, N; De Saeger, C; Horsmans, Y; Leclercq, I; Stärkel, P | 1 |
| Amir, A; Grinboim, E; Kloog, Y; Pinkas-Kramarski, R; Schmukler, E; Schokoroy, S; Wolfson, E | 1 |
| Chen, Y; Gao, X; Huang, Y; Li, J; Li, S; Lu, J; Stolz, DB; Sun, M; Venkataramanan, R; Zhang, L; Zhang, X; Zhao, W | 1 |
| Aizman, E; Chapman, J; Kloog, Y; Mor, A | 1 |
| Barkan, B; Cox, AD; Kloog, Y | 1 |
| Ben-Baruch, G; Faigenbaum, R; Haklai, R; Kloog, Y | 1 |
| Juster, D; Kloog, Y; Pinkas-Kramarski, R; Schokoroy, S | 1 |
| Aizman, E; Ben-Moshe, O; Blacher, E; Kloog, Y; Kogan, T; Mor, A | 1 |
| Chen, L; Huang, Z; Ling, Y; Wang, X; Wang, Z; Zhang, W; Zhang, Y; Zhu, H | 1 |
| Huang, Y; Li, S; Zhang, X | 1 |
| Elad-Sfadia, G; Haklai, R; Kloog, Y; Pinkas-Kramarski, R; Schmukler, E; Wolfson, E | 1 |
| Chen, L; Ling, Y; Wang, X; Wang, Z; Xu, C; Zhang, W; Zhu, H | 1 |
| Herwald, H; Hwaiz, R; Rahman, M; Thorlacius, H; Zhang, S | 1 |
| Chen, Y; Huang, Y; Li, J; Li, S; Lu, J; Zhang, X | 1 |
| Chen, L; Huang, Z; Ling, Y; Wang, X; Wang, Z; Zhang, W; Zhang, Y; Zhao, Y | 1 |
| Abramovitch, S; Elad-Sfadia, G; Haklai, R; Kloog, Y; Neeman, R; Reif, S; Sharvit, E | 1 |
| Chen, Y; Huang, Y; Li, J; Li, S; Venkataramanan, R; Zhang, P; Zhang, X; Zhao, W | 1 |
| Elad-Sfadia, G; Haklai, R; Kloog, Y; Mor, A | 1 |
| Chen, L; Dai, H; Li, X; Ling, Y; Wang, X; Wang, Z; Zhang, W; Zhang, Y | 1 |
| Huang, Y; Li, J; Li, S; Liu, K; Ma, X; Xu, J; Zhang, X | 1 |
| Goldshmit, Y; Kloog, Y; Pinkas-Kramarski, R; Trangle, SS | 1 |
| Luo, L; Merza, M; Thorlacius, H; Yu, C | 1 |
| Ehrlich, M; Gefen-Dor, C; Jacob-Hirsch, J; Kloog, Y; Makovski, V; Rechavi, G; Shai, B | 1 |
| Li, X; Ling, Y; Wang, X; Wang, Z; Yang, Y; Zhang, J; Zhang, Y; Zhao, X | 1 |
| Kloog, Y; Pinkas-Kramarski, R; Schmukler, E; Schokoroy, ST; Wolfson, E | 1 |
| Badar, T; Borthakur, G; Cortes, JE; Garcia-Manero, G; Kantarjian, H; O'Brien, S; Ravandi, F; Verstovsek, S | 1 |
| Ling, Y; Wang, C; Wang, X; Xu, C; Zhang, W; Zhang, Y | 1 |
| Ash, S; Avigad, S; Chepurko, E; Cohen, IJ; Elad-Sfadia, G; Feinmesser, M; Haklai, R; Hameiri-Grossman, M; Issakov, J; Kloog, Y; Kodman, Y; Kollender, Y; Luria, D; Porat-Klein, A; Sher, O; Weizman, A; Yaniv, I | 1 |
| Chordia, MD; Chung, LW; Guan, Y; Li, J; Liu, ZQ; Pan, D; Wang, JP; Xiao, L; Yue, W; Zhang, Y | 1 |
| Ao, F; Chen, L; Gong, X; He, H; Huang, O; Jiang, C; Li, J; Liu, Y; Lu, Y; Song, T; Zhang, C | 1 |
| Djakbarova, U; Gulusur, A; Koseoglu, MM; Ozdilek, BA | 1 |
| Chen, Y; Fu, X; Huang, Y; Li, K; Li, S; Sun, J; Venkataramanan, R; Wei, Y; Xu, L; Zhang, P; Zhang, X; Zhao, W | 1 |
| Hiramatsu, H; Nakabayashi, T; Niwa, Y; Yamaguchi, K | 1 |
| Cheng, KW; Fan, D; Hu, S; Li, ET; Ru, B; Wang, M; Zhang, J; Zhao, Y | 1 |
| Elazar, Z; Kloog, Y; Pinkas-Kramarski, R; Schmukler, E; Wolfson, E | 1 |
| Chen, T; Pang, Y; Qin, G; Wang, X; Wu, L; Wu, S; Xi, G | 1 |
| Goto, K; Ito, S; Kaise, Y; Kato, N; Koike, K; Matsubara, Y; Muroyama, R; Nakagawa, R; Nakano, M; Saeki, C; Saruta, M; Takano, K; Zeniya, M | 1 |
| Bozdağ Pehlivan, S; Buğdaycı, KE; Demir, T; Kaffashi, A; Karlı Oğuz, K; Koşucu, H; Lüle, S; Mut, M; Sarısözen, C; Söylemezoğlu, F; Vural, İ | 1 |
| Bozdağ Pehlivan, S; Gürsoy-Özdemir, Y; Işıkay, I; Kaffashi, A; Kara, A; Lüle, S; Mut, M; Oguz, KK; Öztürk, N; Sekerdag, E; Söylemezoğlu, F; Vural, I; Yavuz, B | 1 |
| Lang, L; Shay, C; Teng, Y; Zhao, X | 1 |
| Chen, L; Chen, T; Wang, Y; Yuan, Z; Zhang, B; Zhang, Y; Zhao, L | 1 |
| Enokida, H; Miyamoto, K; Nakagawa, M; Osako, Y; Sakaguchi, T; Sugita, S; Yonemori, M; Yoshino, H | 1 |
| Fujisaka, Y; Furuse, J; Iwasa, T; Kitamura, H; Kurata, T; Nagashima, F; Nakagawa, K; Naruge, D; Okano, N; Shimizu, T | 1 |
| An, GY; Chen, RX; Huang, C; Liao, ZL; Liu, GA; Wu, JJ; Yuan, XM | 1 |
| Kumar, R; Tseng, YT; Wang, HC | 1 |
| Wang, X; Wang, Y; Yan, L; Zhao, L; Zhu, Y | 1 |
| Chen, M; Goodin, S; Li, D; Liu, W; Ma, Y; Ren, X; Sheng, Z; Xu, X; Zhang, K; Zheng, X; Zhou, R | 1 |
| Azizian, NG; Du, R; Li, Y; Liu, Y; Sullivan, DK | 1 |
| Chen, Y; Cheng, W; Dong, J; Jing, H; Liang, X; Liu, J; Shang, H; Wang, C; Wang, D; Wu, B; Yuan, Y; Zhou, Y | 1 |
| He, J; Huang, C; Huang, H; Jing, X; Li, J; Li, Y; Liu, Q; Tang, Q; Xia, Y; Xu, Y; Yan, J; Zhang, G; Zhang, J; Zhang, T; Zhang, Z; Zhao, Y; Zhou, J | 1 |
| Deng, JH; Guan, Y; Huang, QJ; Huang, ZY; Liao, GC; Liu, ZQ; Lu, LL; Pan, DF; Qi, XX; Wang, Y; Yang, ML; Yao, JJ; Zhang, FX; Zhang, YM; Zhuang, XR | 1 |
| Ballari, MS; Etichetti, CMB; Girardini, JE; Labadie, GR; O J Porta, E; Padrón, JM; Zalazar, EA | 1 |
7 review(s) available for farnesol and salicylates
| Article | Year |
|---|---|
RAS inhibitors: potential for cancer therapeutics.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Drug Design; Enzyme Inhibitors; Farnesol; Farnesyltranstransferase; Humans; Neoplasms; ras Proteins; Salicylates | 2000 |
Inhibitors of chronically active ras: potential for treatment of human malignancies.
Topics: Animals; Antineoplastic Agents; Carnitine O-Palmitoyltransferase; Endopeptidases; Farnesol; Farnesyltranstransferase; Humans; Protein Processing, Post-Translational; ras Proteins; Salicylates | 2008 |
Salirasib in the treatment of pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Membrane; Clinical Trials, Phase I as Topic; Deoxycytidine; Disease-Free Survival; Drug Screening Assays, Antitumor; Farnesol; Farnesyltranstransferase; Galectins; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Middle Aged; Neoplasm Proteins; Neoplasms; Pancreatic Neoplasms; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Salicylates; Signal Transduction | 2010 |
Immunomodulatory properties of farnesoids: the new steroids?
Topics: Animals; Anti-Inflammatory Agents; Autoimmune Diseases; Diabetes Mellitus, Type 2; Disease Models, Animal; Farnesol; Humans; Protein Binding; ras Proteins; Salicylates | 2013 |
Nanomicellar carriers for targeted delivery of anticancer agents.
Topics: Animals; Antineoplastic Agents; Drug Carriers; Drug Delivery Systems; Drug Interactions; Environment; Farnesol; Humans; Nanoparticles; Polymers; Salicylates | 2014 |
Ras chaperones: new targets for cancer and immunotherapy.
Topics: Animals; Antineoplastic Agents; Farnesol; Humans; Immunotherapy; Molecular Chaperones; Neoplasms; ras Proteins; Salicylates; Signal Transduction | 2013 |
Enhancing FTS (Salirasib) efficiency via combinatorial treatment.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Farnesol; Humans; Neoplasms; Salicylates; Signal Transduction | 2015 |
5 trial(s) available for farnesol and salicylates
| Article | Year |
|---|---|
Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Farnesol; Female; Humans; Lymphoma; Male; Middle Aged; Neoplasms; Salicylates; Stereoisomerism | 2010 |
A phase II trial of Salirasib in patients with lung adenocarcinomas with KRAS mutations.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Farnesol; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Salicylates; Survival Rate; Treatment Outcome | 2011 |
Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Farnesol; Female; Gemcitabine; Humans; Male; Mice; Mice, Nude; Middle Aged; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); ras Proteins; Salicylates; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Farnesol; Female; Genes, ras; Humans; Leukemia; Male; Middle Aged; Neoplasm Recurrence, Local; raf Kinases; Salicylates; Signal Transduction; Transcriptional Activation; Treatment Outcome | 2015 |
An early clinical trial of Salirasib, an oral RAS inhibitor, in Japanese patients with relapsed/refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesol; Female; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms; ras Proteins; Salicylates | 2018 |
145 other study(ies) available for farnesol and salicylates
| Article | Year |
|---|---|
Selective inhibition of Ras-dependent cell growth by farnesylthiosalisylic acid.
Topics: Animals; Binding, Competitive; Cell Division; Cell Line; Cell Survival; Cerebellum; Farnesol; In Vitro Techniques; Methylation; Protein Methyltransferases; Proto-Oncogene Proteins p21(ras); Rats; Salicylates; Synaptosomes | 1995 |
Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth.
Topics: Animals; Carboxylic Acids; Cell Division; Cell Line, Transformed; Farnesol; Humans; Protein Methyltransferases; ras Proteins; Rats; Salicylates; Tumor Cells, Cultured | 1995 |
Activation of signaling pathways in HL60 cells and human neutrophils by farnesylthiosalicylate.
Topics: Calcium; Cell Compartmentation; Cysteine; Enzyme Activation; Enzyme Inhibitors; Farnesol; GTP-Binding Proteins; HL-60 Cells; Humans; Inositol 1,4,5-Trisphosphate; NADPH Oxidases; Neutrophils; Pertussis Toxin; Phospholipases; Protein Kinase C; Respiratory Burst; Salicylates; Signal Transduction; Staurosporine; Superoxides; Virulence Factors, Bordetella | 1996 |
The Ras antagonist S-farnesylthiosalicylic acid induces inhibition of MAPK activation.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line; DNA Replication; DNA, Neoplasm; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Epidermal Growth Factor; Farnesol; Humans; Proto-Oncogene Proteins c-raf; ras Proteins; Rats; Retroviridae Proteins, Oncogenic; Salicylates; Thrombin; Thymidine; Tumor Cells, Cultured | 1997 |
Dislodgment and accelerated degradation of Ras.
Topics: Acetylcysteine; Animals; Cell Line, Transformed; Cell Membrane; Cytosol; Farnesol; Growth Inhibitors; Methylation; Oncogene Proteins v-raf; ras Proteins; Rats; Receptor, ErbB-2; Retroviridae Proteins, Oncogenic; Salicylates | 1998 |
Stringent structural requirements for anti-Ras activity of S-prenyl analogues.
Topics: Animals; Cell Division; Cell Line; Cysteine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesol; ras Proteins; Rats; Salicylates; Transfection | 1998 |
Membrane interactions of a constitutively active GFP-Ki-Ras 4B and their role in signaling. Evidence from lateral mobility studies.
Topics: Animals; Binding Sites; Biological Transport; Cell Line; Cell Membrane; Diffusion; Farnesol; Green Fluorescent Proteins; Guanine Nucleotides; Humans; Luminescent Proteins; Microscopy, Confocal; Microscopy, Fluorescence; Rabbits; ras Proteins; Rats; Recombinant Fusion Proteins; Salicylates; Signal Transduction | 1999 |
Growth inhibition of ras-dependent tumors in nude mice by a potent ras-dislodging antagonist.
Topics: 3T3 Cells; Actins; Animals; Antineoplastic Agents; Cell Division; Cell Transformation, Neoplastic; Cytoskeleton; Farnesol; Genes, erbB-2; Genes, ras; Male; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Experimental; Neuroblastoma; Oncogene Proteins v-raf; Protein Prenylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins p21(ras); Rats; Receptor, ErbB-2; Retroviridae Proteins, Oncogenic; Salicylates; Substrate Specificity; Tumor Cells, Cultured | 1999 |
A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice.
Topics: Animals; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinases; Dose-Response Relationship, Drug; Enzyme Activation; Epidermal Growth Factor; Farnesol; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; ras Proteins; Salicylates; Tumor Cells, Cultured | 1999 |
Novel Ras antagonist blocks human melanoma growth.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Line; Cell Line, Transformed; Enzyme Inhibitors; Farnesol; Fibroblasts; Growth Inhibitors; Humans; Melanoma, Experimental; Mice; Mice, SCID; Neoplasm Transplantation; ras Proteins; Rats; Salicylates; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid.
Topics: 3T3 Cells; Animals; Cell Division; Cell Line, Transformed; Cell Membrane; Enzyme Inhibitors; Farnesol; Gene Targeting; Genes, ras; Mice; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Mutation; Protein Isoforms; Proto-Oncogene Proteins p21(ras); Salicylates | 1999 |
The Ras antagonist, farnesylthiosalicylic acid (FTS), inhibits experimentally-induced liver cirrhosis in rats.
Topics: Animals; Antineoplastic Agents; Enzyme Inhibitors; Farnesol; Humans; Liver Cirrhosis, Experimental; Male; ras Proteins; Rats; Rats, Wistar; Salicylates | 1999 |
Farnesylthiosalicylic acid inhibits the growth of human Merkel cell carcinoma in SCID mice.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Merkel Cell; Cell Division; Farnesol; Female; Humans; Injections, Intraperitoneal; Male; Mice; Mice, SCID; Proto-Oncogene Proteins p21(ras); Salicylates; Skin Neoplasms; Statistics, Nonparametric; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |
A novel Ras antagonist regulates both oncogenic Ras and the tumor suppressor p53 in colon cancer cells.
Topics: Blotting, Western; Cell Division; Cell Size; Colonic Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinases; Cyclins; Farnesol; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Mutation; Oligonucleotides, Antisense; Oncogene Protein p21(ras); Salicylates; Transfection; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation | 2000 |
Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by dual activation of the ras-phosphoinositide 3-kinase and jun n-terminal kinase pathways.
Topics: Animals; Animals, Newborn; Apoptosis; Bacterial Proteins; Cells, Cultured; Cerebellum; Dopamine; Enzyme Activation; Enzyme Inhibitors; Escherichia coli; Farnesol; Glutaredoxins; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinases; Models, Neurological; Neurons; NF-kappa B; Oxidoreductases; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; ras Proteins; Salicylates | 2001 |
The Ras-pathway inhibitor, S-trans-trans-farnesylthiosalicylic acid, suppresses experimental allergic encephalomyelitis.
Topics: Animals; Antigens, Surface; Cell Division; Cells, Cultured; Dose-Response Relationship, Drug; Down-Regulation; Drug Administration Schedule; Encephalomyelitis, Autoimmune, Experimental; Enzyme Inhibitors; Farnesol; Female; Lymphocyte Activation; Lymphocytes; Mice; Myelin Proteins; Myelin Sheath; Paralysis; ras Proteins; Salicylates; Survival Rate; Treatment Outcome | 2001 |
Treatment of MRL/lpr mice, a genetic autoimmune model, with the Ras inhibitor, farnesylthiosalicylate (FTS).
Topics: Animals; Antiphospholipid Syndrome; Autoantibodies; Autoimmune Diseases; Farnesol; Female; In Vitro Techniques; Lupus Erythematosus, Systemic; Lymphatic Diseases; Lymphocyte Activation; Lymphocytes; Mice; Mice, Inbred MRL lpr; ras Proteins; Salicylates | 2001 |
The Ras inhibitor S-trans,trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance.
Topics: Actins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Caveolin 1; Caveolins; Deoxycytidine; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Farnesol; Gemcitabine; Humans; MAP Kinase Signaling System; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Phalloidine; ras Proteins; Rats; Salicylates; Time Factors; Tumor Cells, Cultured; Up-Regulation | 2002 |
Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects.
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-Associated Death Protein; Carrier Proteins; Cell Count; Cell Division; Dose-Response Relationship, Drug; Farnesol; Humans; JNK Mitogen-Activated Protein Kinases; Male; Melanoma; Mice; Mitogen-Activated Protein Kinases; p38 Mitogen-Activated Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Retinoblastoma Protein; Salicylates; Time Factors; Tumor Cells, Cultured | 2002 |
Functional inhibition of Ras by S-trans,trans-farnesyl thiosalicylic acid attenuates atherosclerosis in apolipoprotein E knockout mice.
Topics: Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Autoantibodies; Cell Division; Cells, Cultured; Cholesterol; Dietary Fats; Disease Models, Animal; Enzyme Inhibitors; Farnesol; Injections, Intraperitoneal; Lipoproteins, LDL; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; NF-kappa B; ras Proteins; Salicylates; Spleen; Treatment Outcome; Triglycerides; Vascular Cell Adhesion Molecule-1 | 2002 |
Farnesyl thiosalicylic acid chemosensitizes human melanoma in vivo.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Enzyme Inhibitors; Farnesol; Female; Humans; Melanoma, Experimental; Mice; Mice, SCID; Neoplasm Transplantation; ras Proteins; Salicylates; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
Inhibition of ras by farnesylthiosalicylate significantly reduces the levels of autoantibodies in two animal models of the antiphospholipid syndrome.
Topics: Animals; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Autoantibodies; beta 2-Glycoprotein I; Disease Models, Animal; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Farnesol; Female; Freund's Adjuvant; Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Inbred MRL lpr; ras Proteins; Salicylates; Time Factors | 2003 |
Ras antagonist farnesylthiosalicylic acid (FTS) reduces glomerular cellular proliferation and macrophage number in rat thy-1 nephritis.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinases; Cell Division; Enzyme Inhibitors; Farnesol; Isoantibodies; Kidney Glomerulus; Macrophages; Male; Models, Animal; Nephritis; ras Proteins; Rats; Rats, Inbred Lew; Salicylates | 2003 |
Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells.
Topics: 3T3 Cells; Actins; Alkyl and Aryl Transferases; Animals; Apoptosis; Blotting, Western; Cell Cycle; Cell Division; Cisplatin; Colony-Forming Units Assay; Drug Synergism; Enzyme Inhibitors; Farnesol; Farnesyltranstransferase; Humans; In Situ Nick-End Labeling; In Vitro Techniques; Melanoma; Mice; Microscopy, Confocal; Mitogen-Activated Protein Kinases; Piperidines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Retinoblastoma Protein; Salicylates; Skin Neoplasms; Tumor Cells, Cultured | 2003 |
New approaches to the understanding of tamoxifen action and resistance.
Topics: Animals; Antineoplastic Agents, Hormonal; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Drug Resistance, Neoplasm; Estradiol; Farnesol; Female; Humans; Immunoenzyme Techniques; Letrozole; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasm Transplantation; Nitriles; Receptors, Estrogen; Salicylates; Tamoxifen; Triazoles; Tumor Cells, Cultured | 2003 |
The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid exerts long-lasting neuroprotection in a mouse closed head injury model.
Topics: Animals; Brain Injuries; Disease Models, Animal; Enzyme Inhibitors; Farnesol; Guanosine Triphosphate; Head Injuries, Closed; Male; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Neuroprotective Agents; ras Proteins; Receptors, N-Methyl-D-Aspartate; Recovery of Function; Salicylates | 2003 |
Studies on G-protein alpha.betagamma heterotrimer formation reveal a putative S-prenyl-binding site in the alpha subunit.
Topics: Acetylcysteine; Animals; Binding Sites; Binding, Competitive; Cattle; Farnesol; GTP-Binding Protein alpha Subunits; GTP-Binding Protein beta Subunits; GTP-Binding Protein gamma Subunits; Pertussis Toxin; Protein Prenylation; Salicylates; Terpenes; Transducin | 2003 |
Restoration of sensitivity to anoikis in Ras-transformed rat intestinal epithelial cells by a Ras inhibitor.
Topics: Animals; Anoikis; Cell Line, Transformed; Enzyme Inhibitors; Epithelial Cells; Farnesol; Intestines; Oncogene Protein p21(ras); Rats; Salicylates | 2004 |
Inhibition of intimal thickening in the rat carotid artery injury model by a nontoxic Ras inhibitor.
Topics: Animals; Carotid Artery Injuries; Carotid Artery, Common; Cell Division; Cells, Cultured; Disease Models, Animal; Endothelium, Vascular; Enzyme Activation; Farnesol; GTP-Binding Proteins; Immunohistochemistry; Interferon-gamma; Male; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; ras Proteins; Rats; Rats, Wistar; Salicylates; Spleen; Tunica Intima | 2004 |
The novel Ras antagonist, farnesylthiosalicylate, suppresses growth of prostate cancer in vitro.
Topics: Antineoplastic Agents; Cell Division; Cell Line, Tumor; Culture Media; Dihydrotestosterone; Farnesol; Humans; Male; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Salicylates | 2004 |
Terpenes arrest parasite development and inhibit biosynthesis of isoprenoids in Plasmodium falciparum.
Topics: Animals; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Depression, Chemical; Dolichols; Electrophoresis, Polyacrylamide Gel; Erythrocytes; Farnesol; Lipid Metabolism; Malaria, Falciparum; Plasmodium falciparum; Precipitin Tests; Salicylates; Terpenes; Ubiquinone | 2004 |
The c-Raf inhibitor GW5074 provides neuroprotection in vitro and in an animal model of neurodegeneration through a MEK-ERK and Akt-independent mechanism.
Topics: Animals; Cell Death; Cells, Cultured; Disease Models, Animal; Enzyme Inhibitors; Farnesol; Huntington Disease; Indoles; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Neurodegenerative Diseases; Neurons; Neuroprotective Agents; Neurotoxins; Nitro Compounds; Phenols; Propionates; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Rats; Rats, Sprague-Dawley; Salicylates; Signal Transduction | 2004 |
Treatment of thioacetamide-induced liver cirrhosis by the Ras antagonist, farnesylthiosalicylic acid.
Topics: Animals; Apoptosis; Farnesol; Gene Expression; Genes, ras; Hydroxyproline; In Situ Nick-End Labeling; Liver; Liver Cirrhosis, Experimental; Male; Metalloproteases; Organ Size; Rats; Rats, Wistar; Salicylates; Spleen; Thioacetamide; Tissue Inhibitor of Metalloproteinase-2 | 2004 |
Farnesylthiosalicylic acid inhibits mammalian target of rapamycin (mTOR) activity both in cells and in vitro by promoting dissociation of the mTOR-raptor complex.
Topics: Adaptor Proteins, Signal Transducing; Carrier Proteins; Cell Cycle Proteins; Cell Extracts; Cell Line; Farnesol; Humans; Phosphoproteins; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteins; Regulatory-Associated Protein of mTOR; Salicylates; TOR Serine-Threonine Kinases | 2005 |
Characterization of the regulation and functional consequences of p21ras activation in neutrophils by antineutrophil cytoplasm antibodies.
Topics: Antibodies, Antineutrophil Cytoplasmic; Chromones; Enzyme Inhibitors; Farnesol; Humans; Immunoglobulin G; Isomerism; Morpholines; Neutrophils; Proto-Oncogene Proteins p21(ras); Respiratory Burst; Salicylates; Superoxides | 2005 |
Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death.
Topics: Cell Death; Cell Growth Processes; Cell Line, Tumor; Down-Regulation; Farnesol; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Glycolysis; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Phosphatidylinositol 3-Kinases; ras Proteins; Salicylates; Transcription Factors | 2005 |
Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells.
Topics: Apoptosis; Blood; Breast Neoplasms; Cell Division; Cell Line, Tumor; DNA Replication; Enzyme Activation; Epidermal Growth Factor; Estradiol; Farnesol; Humans; Insulin-Like Growth Factor I; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinases; Ribosomal Protein S6 Kinases; Salicylates; Signal Transduction; TOR Serine-Threonine Kinases | 2005 |
Getting at MYC through RAS.
Topics: Cell Line, Tumor; Cell Proliferation; Farnesol; Gene Expression Regulation, Neoplastic; Humans; Models, Biological; Neuroblastoma; Proto-Oncogene Proteins c-myc; ras Proteins; Salicylates; Signal Transduction | 2005 |
Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest.
Topics: Carrier Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p27; Down-Regulation; Farnesol; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Green Fluorescent Proteins; Humans; Immunoblotting; In Situ Hybridization, Fluorescence; Microscopy, Confocal; Mitogen-Activated Protein Kinases; Neuroblastoma; Oligonucleotide Array Sequence Analysis; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; raf Kinases; ras Proteins; Retinoblastoma-Binding Protein 1; Salicylates; Signal Transduction; Transfection; Tumor Suppressor Proteins | 2005 |
The inhibition of human mesangial cell proliferation by S-trans, trans-farnesylthiosalicylic acid.
Topics: Antineoplastic Agents; Apoptosis; Blood Proteins; Cell Division; Cell Membrane; Cells, Cultured; Farnesol; Glomerular Mesangium; Humans; MAP Kinase Signaling System; Platelet-Derived Growth Factor; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; raf Kinases; ras Proteins; Salicylates | 2005 |
Inhibition of Ras attenuates the course of experimental autoimmune neuritis.
Topics: Analysis of Variance; Animals; Behavior, Animal; Body Weight; Cell Proliferation; Cells, Cultured; Concanavalin A; Disease Models, Animal; Dose-Response Relationship, Immunologic; Drug Interactions; Electromyography; Enzyme Inhibitors; Farnesol; Female; Lymphocytes; Motor Activity; Mycobacterium tuberculosis; Myelin Proteins; Neural Conduction; Neuritis, Autoimmune, Experimental; ras Proteins; Rats; Rats, Inbred Lew; Rotarod Performance Test; Salicylates; Severity of Illness Index | 2005 |
Farnesylthiosalicylic acid induces caspase activation and apoptosis in glioblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 9; Caspases; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Farnesol; Glioblastoma; Humans; Mitogen-Activated Protein Kinases; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; ras Proteins; Salicylates; Signal Transduction; Time Factors | 2006 |
Farnesylthiosalicylic acid: inhibition of proliferation and enhancement of apoptosis of hormone-dependent breast cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cyclodextrins; Dose-Response Relationship, Drug; Estradiol; Farnesol; Female; Humans; Injections, Intraperitoneal; Mammary Neoplasms, Experimental; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; ras Proteins; Salicylates; Xenograft Model Antitumor Assays | 2006 |
Antiphospholipid antibodies, thrombin and LPS activate brain endothelial cells and Ras-dependent pathways through distinct mechanisms.
Topics: Animals; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Brain; Cell Line; Endothelial Cells; Extracellular Signal-Regulated MAP Kinases; Farnesol; Female; Humans; Immunoglobulin G; Intercellular Adhesion Molecule-1; Lipopolysaccharides; Male; Phosphorylation; ras Proteins; Rats; Salicylates; Thrombin | 2005 |
Hitting Ras where it counts: Ras antagonism in the basolateral amygdala inhibits long-term fear memory.
Topics: Acoustic Stimulation; Amygdala; Animals; Behavior, Animal; Blotting, Western; Conditioning, Classical; Dose-Response Relationship, Drug; Farnesol; Fear; Male; Memory; Mitogen-Activated Protein Kinase Kinases; ras Proteins; Rats; Rats, Long-Evans; Salicylates; Time Factors | 2006 |
E2F1 identified by promoter and biochemical analysis as a central target of glioblastoma cell-cycle arrest in response to Ras inhibition.
Topics: Cell Cycle; Cell Line, Tumor; Cell Survival; Cyclin D1; Dose-Response Relationship, Drug; E2F1 Transcription Factor; Electrophoretic Mobility Shift Assay; Enzyme Inhibitors; Farnesol; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Green Fluorescent Proteins; Humans; Immunoblotting; Immunohistochemistry; Luciferases; Phosphorylation; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; ras Proteins; Recombinant Fusion Proteins; Retinoblastoma Protein; Salicylates | 2006 |
Using inhibitors of prenylation to block localization and transforming activity.
Topics: Alkyl and Aryl Transferases; Animals; Dimethylallyltranstransferase; Enzyme Inhibitors; Farnesol; Farnesyltranstransferase; GTP Phosphohydrolases; Guanine Nucleotide Dissociation Inhibitors; Mice; NIH 3T3 Cells; Prenylation; Protein Transport; ras Proteins; rho GTP-Binding Proteins; rho-Specific Guanine Nucleotide Dissociation Inhibitors; Salicylates | 2006 |
Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells.
Topics: Amino Acid Chloromethyl Ketones; Androgens; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Dose-Response Relationship, Drug; Down-Regulation; E2F1 Transcription Factor; Farnesol; Humans; Male; Myotonin-Protein Kinase; Prostatic Neoplasms; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; ras Proteins; Salicylates; Serine Proteinase Inhibitors; Signal Transduction | 2006 |
Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis.
Topics: Apoptosis; Caspases; Cell Line, Tumor; Farnesol; Gene Expression; Glioblastoma; Humans; Inhibitor of Apoptosis Proteins; Microtubule-Associated Proteins; Neoplasm Proteins; ras Proteins; RNA, Messenger; Salicylates; Survivin; Transfection | 2006 |
The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Topics: Animals; Antineoplastic Agents; Cell Adhesion; Cell Proliferation; Cytoskeleton; Drug Evaluation; Farnesol; Genes, Neurofibromatosis 1; Genes, ras; Humans; Male; Mice; Mice, Nude; Mutation; Nerve Sheath Neoplasms; Neurofibromatosis 1; Neurofibromin 1; ras Proteins; Salicylates; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |
The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways.
Topics: Animals; Apoptosis; Cell Line, Transformed; Cell Line, Tumor; Cell Survival; Cyclic AMP; Embryo, Mammalian; Extracellular Signal-Regulated MAP Kinases; Farnesol; Fibroblasts; Gene Dosage; Genotype; Humans; Intercellular Signaling Peptides and Proteins; Mice; Neurofibromin 1; Phosphorylation; Protein Kinases; Proto-Oncogene Proteins c-akt; ras Proteins; Salicylates; Simian virus 40; TOR Serine-Threonine Kinases | 2007 |
Angiotensin II-induced MAPK phosphorylation mediated by Ras and/or phospholipase C-dependent phosphorylations but not by protein kinase C phosphorylation in cultured rat vascular smooth muscle cells.
Topics: Angiotensin II; Animals; Blotting, Western; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Inhibitors; Estrenes; Farnesol; Indoles; Losartan; Male; Maleimides; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; Phosphorylation; Protein Kinase C; Pyrrolidinones; ras Proteins; Rats; Rats, Wistar; Receptor, Angiotensin, Type 1; Salicylates; Time Factors; Type C Phospholipases | 2007 |
Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid).
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cluster Analysis; Down-Regulation; Farnesol; Gene Expression; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Promoter Regions, Genetic; ras Proteins; Salicylates; Transcription, Genetic; Up-Regulation | 2007 |
Suppression of lung cancer tumor growth in a nude mouse model by the Ras inhibitor salirasib (farnesylthiosalicylic acid).
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Farnesol; Humans; Lung Neoplasms; Mice; Mice, Nude; ras Proteins; Salicylates | 2007 |
Inhibition of the Ras oncoprotein reduces proliferation of hepatocytes in vitro and in vivo in rats.
Topics: Animals; Body Mass Index; Cell Cycle Proteins; Cell Membrane; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor Proteins; Cytosol; Farnesol; Gene Expression Regulation; Hepatectomy; Hepatocytes; Humans; Liver; Liver Neoplasms, Experimental; Male; MAP Kinase Signaling System; Oncogene Protein p21(ras); Organ Size; Proliferating Cell Nuclear Antigen; Rats; Rats, Wistar; RNA, Messenger; Salicylates; Tumor Cells, Cultured | 2008 |
Hypoxia enhances metastatic efficiency in HT1080 fibrosarcoma cells by increasing cell survival in lungs, not cell adhesion and invasion.
Topics: Animals; Antineoplastic Agents; Cell Adhesion; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Farnesol; Fibrosarcoma; Green Fluorescent Proteins; Humans; Lung Neoplasms; Mice; Mice, SCID; Neoplasm Transplantation; Salicylates; Transplantation, Heterologous | 2007 |
Neuroprotective effects of the Ras inhibitor S-trans-trans-farnesylthiosalicylic acid, measured by diffusion-weighted imaging after traumatic brain injury in rats.
Topics: Animals; Brain Injuries; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Farnesol; Male; Motor Activity; ras Proteins; Rats; Recovery of Function; Salicylates; Time Factors | 2007 |
Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Chromatography, Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Farnesol; Gemcitabine; Injections, Intraperitoneal; Mice; Mice, Nude; Pancreatic Neoplasms; Random Allocation; ras Proteins; Salicylates; Solvents; Survival Rate; Tandem Mass Spectrometry | 2008 |
The effect of Ras inhibition on the proliferation, apoptosis and matrix metalloproteases activity in rat hepatic stellate cells.
Topics: Animals; Apoptosis; Cell Culture Techniques; Cell Line; Cell Proliferation; Collagen Type I; Enzyme Inhibitors; Farnesol; Hepatocytes; Matrix Metalloproteinases; ras Proteins; Rats; Salicylates | 2008 |
Activation of TRPA1 by farnesyl thiosalicylic acid.
Topics: Animals; Calcium; Calcium Channels; Cells, Cultured; CHO Cells; Cricetinae; Cricetulus; Dogs; Electrophysiology; Farnesol; Fluorescence; Ganglia, Spinal; Humans; Ion Channel Gating; Isothiocyanates; Male; Nerve Tissue Proteins; Patch-Clamp Techniques; Rats; Rats, Sprague-Dawley; Ruthenium Red; Salicylates; Transfection; Transient Receptor Potential Channels; TRPA1 Cation Channel | 2008 |
The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cells, Cultured; Farnesol; Humans; Mice; Neoplasms; ras Proteins; Salicylates; Signal Transduction | 2008 |
N-Ras or K-Ras inhibition increases the number and enhances the function of Foxp3 regulatory T cells.
Topics: Adoptive Transfer; Animals; CD4-Positive T-Lymphocytes; Cell Differentiation; Cell Nucleus; Coculture Techniques; Diabetes Mellitus; Enzyme Inhibitors; Farnesol; Forkhead Transcription Factors; Humans; Interleukin-2 Receptor alpha Subunit; Jurkat Cells; Leukocytes, Mononuclear; Lymphocyte Activation; Mice; Mice, Inbred BALB C; NFATC Transcription Factors; Proto-Oncogene Proteins p21(ras); RNA Interference; Salicylates; Spleen; T-Lymphocytes; T-Lymphocytes, Regulatory; Transfection; Up-Regulation | 2008 |
Determination of salirasib (S-trans,trans-farnesylthiosalicylic acid) in human plasma using liquid chromatography-tandem mass spectrometry.
Topics: Administration, Oral; Antineoplastic Agents; Chromatography, Liquid; Farnesol; Humans; Salicylates; Tandem Mass Spectrometry | 2008 |
Salirasib (farnesyl thiosalicylic acid) for brain tumor treatment: a convection-enhanced drug delivery study in rats.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Catheters, Indwelling; Drug Delivery Systems; Farnesol; Magnetic Resonance Imaging; Male; ras Proteins; Rats; Rats, Inbred F344; Salicylates; Signal Transduction | 2008 |
New derivatives of farnesylthiosalicylic acid (salirasib) for cancer treatment: farnesylthiosalicylamide inhibits tumor growth in nude mice models.
Topics: Amides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cyclic AMP-Dependent Protein Kinases; Disease Models, Animal; Disease Progression; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Farnesol; Humans; MAP Kinase Signaling System; Mice; Mice, Nude; Molecular Structure; Neoplasms; Oncogene Protein p21(ras); Salicylates; Xenograft Model Antitumor Assays | 2009 |
Ras inhibition attenuates myocardial ischemia-reperfusion injury.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Farnesol; Heart Function Tests; In Vitro Techniques; Male; Myocardial Reperfusion Injury; Myocardium; ras Proteins; Rats; Rats, Inbred Lew; Rats, Wistar; Salicylates | 2009 |
The Ras inhibitor farnesylthiosalicyclic acid (FTS) prevents nodule formation and development of preneoplastic foci of altered hepatocytes in rats.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers; Blotting, Western; Carcinoma, Hepatocellular; Caspase 3; Caspase 8; Diethylnitrosamine; Farnesol; Gene Expression Regulation, Neoplastic; Genes, ras; Hepatocytes; Immunohistochemistry; Liver Neoplasms; Male; Models, Animal; Rats; Rats, Wistar; Salicylates | 2009 |
Novel farnesylthiosalicylate (FTS)-eluting composite structures.
Topics: Algorithms; Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Drug Compounding; Drug Stability; Drug-Eluting Stents; Emulsions; Farnesol; Indicators and Reagents; Kinetics; Metals; Microscopy, Electron, Scanning; Paclitaxel; Porosity; Salicylates; Solubility; Tensile Strength | 2009 |
Ras inhibition increases the frequency and function of regulatory T cells and attenuates type-1 diabetes in non-obese diabetic mice.
Topics: Animals; Diabetes Mellitus, Type 1; Enzyme Inhibitors; Farnesol; Forkhead Transcription Factors; Homeostasis; Interleukin-2 Receptor alpha Subunit; Male; Mice; Mice, Inbred NOD; Proto-Oncogene Proteins p21(ras); Salicylates; T-Lymphocytes, Regulatory; Up-Regulation | 2009 |
Differential requirement of CAAX-mediated posttranslational processing for Rheb localization and signaling.
Topics: Animals; Binding Sites; Blotting, Western; Cell Line, Tumor; Chlorocebus aethiops; COS Cells; Endoplasmic Reticulum; Farnesol; Golgi Apparatus; Green Fluorescent Proteins; Humans; Intracellular Signaling Peptides and Proteins; Mice; Microscopy, Fluorescence; Monomeric GTP-Binding Proteins; Mutation; Neuropeptides; NIH 3T3 Cells; Phosphorylation; Prenylation; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Ras Homolog Enriched in Brain Protein; Rats; Ribosomal Protein S6 Kinases, 70-kDa; Salicylates; Signal Transduction; TOR Serine-Threonine Kinases; Transfection | 2010 |
Ras inhibits endoplasmic reticulum stress in human cancer cells with amplified Myc.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; eIF-2 Kinase; Endoplasmic Reticulum; Enzyme Inhibitors; Farnesol; Gene Amplification; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Mitogen-Activated Protein Kinase Kinases; N-Myc Proto-Oncogene Protein; Neuroblastoma; NF-E2-Related Factor 2; Nuclear Proteins; Oncogene Proteins; ras Proteins; RNA, Small Interfering; Salicylates; Transcription Factors; Unfolded Protein Response | 2010 |
Synthesis and evaluation of nitric oxide-releasing derivatives of farnesylthiosalicylic acid as anti-tumor agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Farnesol; Genes, ras; Humans; Nitric Oxide; Oxadiazoles; Salicylates; Signal Transduction; Structure-Activity Relationship | 2010 |
Dynamic changes in the TRPA1 selectivity filter lead to progressive but reversible pore dilation.
Topics: Animals; Benzamides; Benzoxazoles; Calcium; Calcium Channels; Carbamates; Cell Membrane; Cell Membrane Permeability; CHO Cells; Cricetinae; Cricetulus; Dogs; Dose-Response Relationship, Drug; Farnesol; Humans; Ion Channel Gating; Isothiocyanates; Kinetics; Meglumine; Membrane Transport Modulators; Nerve Tissue Proteins; Purinergic P2 Receptor Agonists; Quinolinium Compounds; Rats; Receptors, Purinergic P2; Receptors, Purinergic P2X7; Salicylates; Transfection; Transient Receptor Potential Channels; TRPA1 Cation Channel; TRPM Cation Channels; TRPV Cation Channels | 2010 |
Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aurora Kinases; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Down-Regulation; Farnesol; Flow Cytometry; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Protein Serine-Threonine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Salicylates; Survivin; Valproic Acid | 2011 |
Proto-oncogenic H-Ras, K-Ras, and N-Ras are involved in muscle differentiation via phosphatidylinositol 3-kinase.
Topics: Animals; Cell Differentiation; Cell Line; Farnesol; Membrane Glycoproteins; Muscle Development; Myocardium; NADPH Oxidase 2; NADPH Oxidases; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase Type II; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins p21(ras); Rats; RNA Interference; RNA, Small Interfering; Salicylates; Signal Transduction | 2010 |
Composite fiber structures with antiproliferative agents exhibit advantageous drug delivery and cell growth inhibition in vitro.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Delivery Systems; Drug-Eluting Stents; Enzyme Inhibitors; Farnesol; Humans; Kinetics; Lactic Acid; Paclitaxel; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polymers; ras Proteins; Rats; Salicylates; Solubility | 2011 |
Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas.
Topics: Animals; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Disease Models, Animal; Down-Regulation; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Farnesol; Galectin 3; Gene Expression Regulation, Neoplastic; Guanosine Triphosphate; Humans; Mice; Nuclear Proteins; Protein Transport; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Salicylates; Signal Transduction; Thyroid Neoplasms; Thyroid Nuclear Factor 1; Transcription Factors; Xenograft Model Antitumor Assays | 2010 |
Inhibitory effect of farnesylthiosalicylic acid on mediators release by mast cells: preferential inhibition of prostaglandin D(2) and tumor necrosis factor-α release.
Topics: Animals; Cell Degranulation; Cell Line; Farnesol; Female; Humans; Mast Cells; Mice; Mice, Inbred BALB C; Passive Cutaneous Anaphylaxis; Prostaglandin D2; ras Proteins; Salicylates; Tumor Necrosis Factor-alpha | 2011 |
Salirasib inhibits the growth of hepatocarcinoma cell lines in vitro and tumor growth in vivo through ras and mTOR inhibition.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cyclin A; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Epidermal Growth Factor; Extracellular Signal-Regulated MAP Kinases; Farnesol; Female; Hep G2 Cells; Humans; Inhibitor of Apoptosis Proteins; Insulin-Like Growth Factor II; Liver Neoplasms; Mice; Mice, Nude; Microtubule-Associated Proteins; ras Proteins; Reverse Transcriptase Polymerase Chain Reaction; Salicylates; Survivin; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2010 |
The combined treatment of Copaxone and Salirasib attenuates experimental autoimmune encephalomyelitis (EAE) in mice.
Topics: Animals; Carrier Proteins; CD3 Complex; Cell Proliferation; Cytokines; Demyelinating Diseases; Disease Models, Animal; DNA Helicases; Drug Synergism; Drug Therapy, Combination; Encephalomyelitis, Autoimmune, Experimental; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Extracellular Signal-Regulated MAP Kinases; Farnesol; Female; Forkhead Transcription Factors; Glatiramer Acetate; Immunosuppressive Agents; Leukemic Infiltration; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Peptides; Poly-ADP-Ribose Binding Proteins; RNA Helicases; RNA Recognition Motif Proteins; Salicylates; Spinal Cord; Spleen; Statistics, Nonparametric; Time Factors | 2010 |
Multiple cellular proteins modulate the dynamics of K-ras association with the plasma membrane.
Topics: Amino Acid Sequence; Calmodulin; Cell Membrane; Cyclic Nucleotide Phosphodiesterases, Type 6; Farnesol; Galectin 3; GTP-Binding Proteins; HeLa Cells; Humans; Intracellular Space; Kinetics; Microscopy, Confocal; Molecular Sequence Data; Peptides; Prenylation; Protein Binding; Proto-Oncogene Proteins p21(ras); Salicylates; Sirolimus; Vesicular Transport Proteins | 2010 |
The Ras antagonist, farnesylthiosalicylic acid (FTS), decreases fibrosis and improves muscle strength in dy/dy mouse model of muscular dystrophy.
Topics: Animals; Base Sequence; Blotting, Western; Disease Models, Animal; DNA Primers; Farnesol; Fibrosis; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred C57BL; Muscle Strength; Muscular Dystrophies; ras Proteins; Salicylates | 2011 |
Farnesylthiosalicylic acid (salirasib) inhibits Rheb in TSC2-null ELT3 cells: a potential treatment for lymphangioleiomyomatosis.
Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cysteine; Farnesol; Lymphangioleiomyomatosis; Lymphocytes, Null; Mice; Mice, Nude; Monomeric GTP-Binding Proteins; Mutation; Neuropeptides; Phosphorylation; Ras Homolog Enriched in Brain Protein; ras Proteins; Rats; Ribosomal Protein S6 Kinases; Salicylates; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2012 |
Novel nitric oxide-releasing derivatives of farnesylthiosalicylic acid: synthesis and evaluation of antihepatocellular carcinoma activity.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Extracellular Signal-Regulated MAP Kinases; Farnesol; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Nitric Oxide Donors; Oxadiazoles; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Salicylates; Stereoisomerism; Structure-Activity Relationship; Toxicity Tests, Acute; Transplantation, Heterologous | 2011 |
Chemoprevention of hepatocellular carcinoma. Proof of concept in animal models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Models, Animal; Farnesol; Humans; Hypoglycemic Agents; Liver Neoplasms; Peptides, Cyclic; Pioglitazone; Salicylates; Somatostatin; Thiazolidinediones | 2011 |
ZL11n is a novel nitric oxide-releasing derivative of farnesylthiosalicylic acid that induces apoptosis in human hepatoma HepG2 cells via MAPK/mitochondrial pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Enzyme Activation; Farnesol; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred ICR; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Nitric Oxide; Oxadiazoles; Salicylates | 2011 |
Phenotypic reversion of invasive neurofibromin-deficient schwannoma by FTS: Ras inhibition reduces BMP4/Erk/Smad signaling.
Topics: Antineoplastic Agents; Bone Morphogenetic Protein 4; Cell Line, Tumor; Cell Movement; Extracellular Signal-Regulated MAP Kinases; Farnesol; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Models, Biological; Neurilemmoma; Neurofibromin 1; Phenotype; ras Proteins; Salicylates; Signal Transduction; Smad Proteins; Transforming Growth Factor beta | 2011 |
Inhibition of contact sensitivity by farnesylthiosalicylic acid-amide, a potential Rap1 inhibitor.
Topics: Amides; Animals; Cell Membrane; Disease Models, Animal; Farnesol; Female; Green Fluorescent Proteins; Guanosine Triphosphate; Humans; Immunohistochemistry; Jurkat Cells; Lymphocytes; Mice; Mice, Inbred BALB C; Phospholipase D; rap1 GTP-Binding Proteins; ras Proteins; Salicylates; Shelterin Complex; Skin; T-Lymphocytes; Telomere-Binding Proteins; Tumor Necrosis Factor-alpha | 2011 |
Ras inhibition induces insulin sensitivity and glucose uptake.
Topics: Animals; Blotting, Western; Cell Line; Diabetes Mellitus, Type 2; Farnesol; Glucose; Insulin Resistance; Mice; Polymerase Chain Reaction; Proto-Oncogene Proteins p21(ras); Salicylates | 2011 |
Ras inhibition in hepatocarcinoma by S-trans-trans-farnesylthiosalicyclic acid: association of its tumor preventive effect with cell proliferation, cell cycle events, and angiogenesis.
Topics: Animals; Anticarcinogenic Agents; Carcinogens; Cell Cycle; Cell Proliferation; Cyclin D; Diethylnitrosamine; Disease Models, Animal; Down-Regulation; Farnesol; Inflammation; Liver Neoplasms, Experimental; Male; Neovascularization, Pathologic; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-myc; ras Proteins; Rats; Rats, Wistar; Salicylates; STAT3 Transcription Factor | 2012 |
Prevention of induced colitis in mice by the ras antagonist farnesylthiosalicylic acid.
Topics: Animals; Blotting, Western; Colitis; Colon; Enzyme Inhibitors; Farnesol; Female; Flow Cytometry; Interleukin-1beta; Mice; Mice, Inbred BALB C; Organ Culture Techniques; ras Proteins; Salicylates; Tumor Necrosis Factor-alpha | 2012 |
Ras inhibition by FTS attenuates brain tumor growth in mice by direct antitumor activity and enhanced reactivity of cytotoxic lymphocytes.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Farnesol; Forkhead Transcription Factors; Glioma; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Molecular Targeted Therapy; Oncogene Protein v-akt; Proto-Oncogene Proteins p21(ras); ras Proteins; RNA, Messenger; Salicylates; T-Lymphocytes, Cytotoxic; Transforming Growth Factor beta | 2012 |
Analgesic potential of intrathecal farnesyl thiosalicylic acid and GW 5074 in vincristine-induced neuropathic pain in rats.
Topics: Analgesics; Animals; Farnesol; Female; Indoles; Injections, Spinal; Male; Neuralgia; Phenols; Rats; Rats, Wistar; Salicylates; Vincristine | 2012 |
FTS and 2-DG induce pancreatic cancer cell death and tumor shrinkage in mice.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Proliferation; Deoxyglucose; Drug Synergism; Farnesol; Glycolysis; Humans; Mice; Mice, Nude; Organ Size; Pancreas; Pancreatic Neoplasms; Salicylates; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Lipid rafts and functional caveolae regulate HIV-induced amyloid beta accumulation in brain endothelial cells.
Topics: Amyloid beta-Peptides; Brain; Caveolae; Cells, Cultured; Endothelial Cells; Enzyme Inhibitors; Farnesol; HIV Infections; HIV-1; Humans; Membrane Microdomains; ras Proteins; Receptor for Advanced Glycation End Products; Receptors, Immunologic; Salicylates | 2012 |
Celecoxib enhances the anti-inflammatory effects of farnesylthiosalicylic acid on T cells independent of prostaglandin E(2) production.
Topics: Animals; Celecoxib; Cell Adhesion; Cell Line; Cyclooxygenase 2 Inhibitors; Dinoprostone; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Farnesol; Humans; Interleukin-2; Jurkat Cells; Mice; Mice, Inbred BALB C; Oncogene Protein p21(ras); Phosphorylation; Pyrazoles; Salicylates; Sulfonamides; T-Lymphocytes | 2012 |
Computer-based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton.
Topics: Actin Cytoskeleton; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Proliferation; Drug Synergism; Farnesol; Humans; Isoxazoles; Lim Kinases; Mice; Mice, Knockout; Neurofibromin 1; Protein Kinase Inhibitors; Salicylates | 2012 |
Mechanisms of antiproliferative drug release from bioresorbable porous structures.
Topics: Antineoplastic Agents; Biocompatible Materials; Drug-Eluting Stents; Farnesol; Humans; Models, Molecular; Neoplasms; Paclitaxel; Polyglactin 910; Porosity; Salicylates; Sirolimus; Solubility | 2013 |
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colorectal Neoplasms; Drug Synergism; Farnesol; Gene Expression Regulation, Neoplastic; Humans; Mice; Perylene; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrvinium Compounds; ras Proteins; Salicylates; Wnt Proteins | 2012 |
Salirasib sensitizes hepatocarcinoma cells to TRAIL-induced apoptosis through DR5 and survivin-dependent mechanisms.
Topics: Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Caspase 8; Caspase 9; Cell Line, Tumor; Farnesol; Hep G2 Cells; Hepatocytes; Humans; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Mitochondria; Receptors, TNF-Related Apoptosis-Inducing Ligand; Recombinant Proteins; Salicylates; Survivin; TNF-Related Apoptosis-Inducing Ligand | 2013 |
Ras inhibition enhances autophagy, which partially protects cells from death.
Topics: Animals; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 5; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Embryo, Mammalian; Farnesol; Fibroblasts; Green Fluorescent Proteins; HCT116 Cells; HeLa Cells; Humans; Immunoblotting; Mice; Mice, Knockout; Microscopy, Fluorescence; Microtubule-Associated Proteins; ras Proteins; Salicylates | 2013 |
PEG-farnesylthiosalicylate conjugate as a nanomicellar carrier for delivery of paclitaxel.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Drug Delivery Systems; Farnesol; Female; HCT116 Cells; Humans; Mice; Mice, Inbred BALB C; Micelles; Paclitaxel; Polyethylene Glycols; Random Allocation; Rats; Salicylates | 2013 |
Ras inhibition boosts galectin-7 at the expense of galectin-1 to sensitize cells to apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Cell Growth Processes; Farnesol; Galactosides; Galectin 1; Galectins; Humans; Nerve Sheath Neoplasms; Neurofibromin 1; ras Proteins; Salicylates; Transcription, Genetic | 2013 |
Growth of poorly differentiated endometrial carcinoma is inhibited by combined action of medroxyprogesterone acetate and the Ras inhibitor Salirasib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Cell Growth Processes; Cell Line, Tumor; Down-Regulation; Endometrial Neoplasms; Estrogen Receptor alpha; Estrogen Receptor beta; Farnesol; Female; Gene Expression Regulation, Neoplastic; Humans; Medroxyprogesterone Acetate; Phosphorylation; ras Proteins; RNA, Messenger; Salicylates; Transcription, Genetic | 2013 |
Disrupting the oncogenic synergism between nucleolin and Ras results in cell growth inhibition and cell death.
Topics: Animals; Aptamers, Nucleotide; Carcinogenesis; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; ErbB Receptors; Farnesol; Humans; Immunoblotting; Immunohistochemistry; Mice; Mice, Nude; Microscopy, Fluorescence; Nucleolin; Oligodeoxyribonucleotides; Phosphoproteins; ras Proteins; RNA-Binding Proteins; Salicylates | 2013 |
Therapeutic effect of farnesylthiosalicylic acid on adjuvant-induced arthritis through suppressed release of inflammatory cytokines.
Topics: Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Cytokines; Disease Models, Animal; Farnesol; Inflammation Mediators; Joints; Male; ras GTPase-Activating Proteins; Rats; Salicylates; Signal Transduction; T-Lymphocyte Subsets | 2014 |
Synthesis and biological evaluation of farnesylthiosalicylamides as potential anti-tumor agents.
Topics: Antineoplastic Agents; Apoptosis; Farnesol; Humans; Neoplasms; Salicylates; Signal Transduction | 2014 |
Chloroquine synergizes with FTS to enhance cell growth inhibition and cell death.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Chloroquine; Farnesol; HCT116 Cells; Humans; ras Proteins; Rats; Salicylates; Signal Transduction; TOR Serine-Threonine Kinases | 2014 |
Synthesis and biological evaluation of novel farnesylthiosalicylic acid derivatives for cancer treatment.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; Farnesol; Flow Cytometry; Humans; Inhibitory Concentration 50; MAP Kinase Signaling System; Molecular Structure; ras Proteins; Salicylates; Structure-Activity Relationship | 2014 |
Ras regulates alveolar macrophage formation of CXC chemokines and neutrophil activation in streptococcal M1 protein-induced lung injury.
Topics: Animals; Antigens, Bacterial; Bacterial Outer Membrane Proteins; Bronchoalveolar Lavage Fluid; Carrier Proteins; Chemokines, CXC; Enzyme-Linked Immunosorbent Assay; Farnesol; Flow Cytometry; Lung; Lung Injury; Macrophages, Alveolar; Male; Mice, Inbred C57BL; Neutrophil Infiltration; Pulmonary Edema; ras Proteins; Salicylates; Signal Transduction | 2014 |
Targeted delivery of curcumin to tumors via PEG-derivatized FTS-based micellar system.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Curcumin; Drug Delivery Systems; Farnesol; Female; Mice; Mice, Inbred BALB C; Micelles; NF-kappa B; Polyethylene Glycols; Proto-Oncogene Proteins c-akt; Salicylates; Signal Transduction | 2014 |
Synthesis and biological evaluation of hybrids from farnesylthiosalicylic acid and hydroxylcinnamic acid with dual inhibitory activities of Ras-related signaling and phosphorylated NF-κB.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Coumaric Acids; Farnesol; Humans; Immunoblotting; Inhibitory Concentration 50; Mice; NF-kappa B; Phosphorylation; ras Proteins; Salicylates; Signal Transduction | 2014 |
Vitamin D and S-farnesylthiosalicylic acid have a synergistic effect on hepatic stellate cells proliferation.
Topics: Animals; Biomarkers; Calcitriol; Cell Proliferation; Cyclin D1; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Farnesol; Gene Expression Regulation; Hepatic Stellate Cells; Male; ras Proteins; Rats; Rats, Wistar; Salicylates | 2014 |
PEG-farnesyl thiosalicylic acid telodendrimer micelles as an improved formulation for targeted delivery of paclitaxel.
Topics: Animals; Breast Neoplasms; Disease Models, Animal; Drug Carriers; Farnesol; Female; HCT116 Cells; Hemolysis; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Mammary Neoplasms, Experimental; MCF-7 Cells; Mice; Mice, Inbred BALB C; Micelles; Paclitaxel; Polyethylene Glycols; Salicylates | 2014 |
Hybrid molecule from Farnesylthiosalicylic acid-diamine and phenylpropenoic acid as Ras-related signaling inhibitor with potent antitumor activities.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Diamines; Farnesol; Humans; Neoplasms; NF-kappa B; Phenylpropionates; Phosphorylation; ras Proteins; Salicylates; Signal Transduction | 2015 |
Reduction-sensitive dual functional nanomicelles for improved delivery of paclitaxel.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Carriers; Farnesol; Female; Humans; Hydrophobic and Hydrophilic Interactions; Mammary Neoplasms, Experimental; Mice; Micelles; Nanostructures; Oxidation-Reduction; Paclitaxel; Polyethylene Glycols; Salicylates | 2014 |
Interfering with the interaction between ErbB1, nucleolin and Ras as a potential treatment for glioblastoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aptamers, Nucleotide; Brain Neoplasms; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; ErbB Receptors; Farnesol; Glioblastoma; Humans; Mice, Nude; Nucleolin; Oligodeoxyribonucleotides; Phosphoproteins; Phosphorylation; ras Proteins; Receptor Cross-Talk; RNA-Binding Proteins; Salicylates; Signal Transduction; Time Factors; Tumor Burden | 2014 |
Inhibition of Ras signalling reduces neutrophil infiltration and tissue damage in severe acute pancreatitis.
Topics: Acinar Cells; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemokines; Enzyme Inhibitors; Farnesol; HMGB1 Protein; Interleukin-6; Macrophage-1 Antigen; Male; Mice, Inbred C57BL; Molecular Targeted Therapy; Neutrophil Infiltration; Neutrophils; Pancreas; Pancreatitis, Acute Necrotizing; Proto-Oncogene Proteins p21(ras); Salicylates; Signal Transduction | 2015 |
Analysis of gene expression array in TSC2-deficient AML cells reveals IRF7 as a pivotal factor in the Rheb/mTOR pathway.
Topics: Angiomyolipoma; Cell Proliferation; Farnesol; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Interferon Regulatory Factor-7; Kidney; Lymphangioleiomyomatosis; Microarray Analysis; Monomeric GTP-Binding Proteins; Neuropeptides; Ras Homolog Enriched in Brain Protein; RNA, Small Interfering; Salicylates; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 2 Protein; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2014 |
Novel FTS-diamine/cinnamic acid hybrids inhibit tumor cell proliferation and migration and promote apoptosis via blocking Ras-related signaling in vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cinnamates; Drug Resistance, Neoplasm; Farnesol; Genes, ras; Humans; Mice; Mice, Inbred ICR; Neoplasms, Experimental; Salicylates; Signal Transduction; Solubility; Wound Healing | 2015 |
Hybrids from Farnesylthiosalicylic Acid and Hydroxamic Acid as Dual Ras-Related Signaling and Histone Deacetylase (HDAC) Inhibitors: Design, Synthesis and Biological Evaluation.
Topics: Cell Line; Drug Design; Drug Evaluation, Preclinical; Farnesol; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Salicylates | 2015 |
The association between let-7, RAS and HIF-1α in Ewing Sarcoma tumor growth.
Topics: Adolescent; Adult; Animals; Antineoplastic Agents; Cell Cycle; Cell Movement; Cell Survival; Child; Child, Preschool; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 22; Disease-Free Survival; Farnesol; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Tumor Suppressor; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Infant; Male; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Neoplasm Transplantation; Oncogene Proteins, Fusion; Proto-Oncogene Protein c-fli-1; Random Allocation; ras Proteins; RNA-Binding Protein EWS; Salicylates; Sarcoma, Ewing; Signal Transduction; Young Adult | 2015 |
Improving Therapeutic Potential of Farnesylthiosalicylic Acid: Tumor Specific Delivery via Conjugation with Heptamethine Cyanine Dye.
Topics: Animals; Antineoplastic Agents; Biological Availability; Breast Neoplasms; Carbocyanines; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Farnesol; Female; Humans; MCF-7 Cells; Mice; Mice, Nude; ras Proteins; Salicylates; Tissue Distribution; TOR Serine-Threonine Kinases | 2017 |
RAS Promotes Proliferation and Resistances to Apoptosis in Meningioma.
Topics: Adult; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Double-Blind Method; Farnesol; Female; Humans; Male; Meningeal Neoplasms; Meningioma; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Random Allocation; ras Proteins; Salicylates; Tumor Cells, Cultured | 2017 |
Targeting Ras Activity Prevented Amyloid Beta-Induced Aberrant Neuronal Cell Cycle Re-Entry and Death.
Topics: Amyloid beta-Peptides; Cell Cycle; Cell Death; Cell Differentiation; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesol; Gene Expression Regulation; Humans; Microtubule-Associated Proteins; Neuroblastoma; Neurons; Peptide Fragments; ras Proteins; Salicylates; Time Factors | 2016 |
A prodrug micellar carrier assembled from polymers with pendant farnesyl thiosalicylic acid moieties for improved delivery of paclitaxel.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Drug Delivery Systems; Drug Liberation; Dynamic Light Scattering; Farnesol; Humans; Kaplan-Meier Estimate; Mice; Micelles; Paclitaxel; Polyethylene Glycols; Polymerization; Polymers; Prodrugs; Proton Magnetic Resonance Spectroscopy; Salicylates; Spectroscopy, Near-Infrared | 2016 |
Generation of self-clusters of galectin-1 in the farnesyl-bound form.
Topics: Binding Sites; Farnesol; Galectin 1; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Molecular Dynamics Simulation; Protein Binding; Protein Conformation; Protein Processing, Post-Translational; Proto-Oncogene Proteins p21(ras); Salicylates | 2016 |
6-C-(E-phenylethenyl)naringenin induces cell growth inhibition and cytoprotective autophagy in colon cancer cells.
Topics: Autophagy; Autophagy-Related Protein 7; Beclin-1; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Enzyme Inhibitors; Farnesol; Flavanones; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HCT116 Cells; HT29 Cells; Humans; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Molecular Docking Simulation; Necrosis; Phosphatidylinositol 3-Kinases; Protein Methyltransferases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; ras Proteins; Salicylates; TOR Serine-Threonine Kinases | 2016 |
Continuous treatment with FTS confers resistance to apoptosis and affects autophagy.
Topics: Apoptosis; Autophagy; Cell Death; Cell Survival; Drug Resistance, Neoplasm; Farnesol; Genes, ras; HCT116 Cells; Humans; Real-Time Polymerase Chain Reaction; Salicylates; Signal Transduction | 2017 |
Farnesylthiosalicylic acid sensitizes hepatocarcinoma cells to artemisinin derivatives.
Topics: Acetylcysteine; Antineoplastic Agents; Apoptosis; Artemisinins; Carcinoma, Hepatocellular; Drug Synergism; Farnesol; Hep G2 Cells; Humans; Liver Neoplasms; Salicylates | 2017 |
miR-425 regulates inflammatory cytokine production in CD4
Topics: Aged; Case-Control Studies; CD4-Positive T-Lymphocytes; Cytokines; Farnesol; Gene Expression Profiling; Genes, ras; Humans; Inflammation Mediators; Interferon-gamma; Interleukin-2; Jurkat Cells; Liver Cirrhosis, Biliary; MicroRNAs; Middle Aged; Oligonucleotide Array Sequence Analysis; Receptors, Antigen, T-Cell; RNA, Messenger; Salicylates; Signal Transduction; Up-Regulation | 2017 |
Farnesylthiosalicylic acid-loaded lipid-polyethylene glycol-polymer hybrid nanoparticles for treatment of glioblastoma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Farnesol; Female; Glioblastoma; Lipids; Nanoparticles; Polyethylene Glycols; Polymers; Rats; Rats, Wistar; Salicylates; Treatment Outcome; Tumor Burden | 2017 |
A potential non-invasive glioblastoma treatment: Nose-to-brain delivery of farnesylthiosalicylic acid incorporated hybrid nanoparticles.
Topics: Administration, Intranasal; Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Drug Carriers; Drug Delivery Systems; Farnesol; Female; Glioblastoma; Lipids; Magnetic Resonance Imaging; Nanoparticles; Polyesters; Polyethylene Glycols; Rats; Rats, Wistar; Salicylates; Treatment Outcome | 2017 |
Combined targeting of Arf1 and Ras potentiates anticancer activity for prostate cancer therapeutics.
Topics: ADP-Ribosylation Factor 1; Animals; Antineoplastic Agents; Apoptosis; Benzaldehydes; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Farnesol; Humans; Male; Mice; Prostatic Neoplasms; Pyrimidines; ras Proteins; Salicylates; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Ras inhibitor S-trans, trans-farnesylthiosalicylic acid enhances spatial memory and hippocampal long-term potentiation via up-regulation of NMDA receptor.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cyclic AMP Response Element-Binding Protein; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Farnesol; Hippocampus; Long-Term Potentiation; Male; Maze Learning; Mice, Inbred ICR; Neurons; Nootropic Agents; Phosphorylation; ras Proteins; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Salicylates; Spatial Memory; src-Family Kinases; Tissue Culture Techniques; Up-Regulation | 2018 |
HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Farnesol; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Regulatory Networks; Glycolysis; Humans; Mice; Mutation; Oxidative Phosphorylation; Proteomics; Proto-Oncogene Mas; Proto-Oncogene Proteins p21(ras); Salicylates; Up-Regulation; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2018 |
Farnesyl thiosalicylic acid prevents iNOS induction triggered by lipopolysaccharide via suppression of iNOS mRNA transcription in murine macrophages.
Topics: Animals; Cells, Cultured; Farnesol; Lipopolysaccharides; Liver; Lung; Macrophages; Male; Mice, Inbred C57BL; NF-kappa B; Nitric Oxide; Nitric Oxide Synthase Type II; RNA, Messenger; Salicylates | 2019 |
LvRas and LvRap are both important for WSSV replication in Litopenaeus vannamei.
Topics: Animals; Aquaculture; Enzyme Inhibitors; Farnesol; Hemocytes; Penaeidae; Phosphatidylinositol 3-Kinases; Protein Isoforms; Proto-Oncogene Proteins c-akt; rab GTP-Binding Proteins; ras Proteins; RNA Interference; RNA, Double-Stranded; Salicylates; TOR Serine-Threonine Kinases; Virus Replication; White spot syndrome virus 1 | 2019 |
Neuroprotective Effect of S-trans, Trans-farnesylthiosalicylic Acid via Inhibition of RAS/ERK Pathway for the Treatment of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Disease Models, Animal; Doublecortin Protein; Extracellular Signal-Regulated MAP Kinases; Farnesol; Injections, Intraperitoneal; Male; MAP Kinase Signaling System; Maze Learning; Mice; Mice, Inbred ICR; Molecular Structure; Neuroprotective Agents; ras Proteins; Salicylates; Stereoisomerism | 2019 |
Celecoxib combined with salirasib strongly inhibits pancreatic cancer cells in 2D and 3D cultures.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase 3; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Farnesol; Gene Expression Regulation, Neoplastic; Humans; NF-kappa B; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Salicylates; Signal Transduction | 2020 |
Inhibition of ERAD synergizes with FTS to eradicate pancreatic cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; CRISPR-Cas Systems; Drug Screening Assays, Antitumor; Endoplasmic Reticulum-Associated Degradation; Farnesol; Gene Knockout Techniques; Humans; Hydrazones; Hydroxyurea; Mice; Pancreatic Neoplasms; Proteins; Salicylates; Synthetic Lethal Mutations; Ubiquitin-Protein Ligases; Unfolded Protein Response | 2021 |
Single-cell RNA sequencing reveals the mechanism of sonodynamic therapy combined with a RAS inhibitor in the setting of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Combined Modality Therapy; Diathermy; Disease Models, Animal; Endothelial Cells; Farnesol; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; ras Proteins; Salicylates; Sequence Analysis, RNA | 2021 |
Farnesylthiosalicylic Acid-Loaded Albumin Nanoparticle Alleviates Renal Fibrosis by Inhibiting Ras/Raf1/p38 Signaling Pathway.
Topics: Albumins; Animals; Farnesol; Fibrosis; Mice; Nanoparticles; Proto-Oncogene Proteins c-raf; Rats; Rats, Sprague-Dawley; Salicylates; Signal Transduction; Tissue Distribution | 2021 |
Ras inhibitor farnesylthiosalicylic acid conjugated with IR783 dye exhibits improved tumor-targeting and altered anti-breast cancer mechanisms in mice.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Farnesol; Female; Humans; Mice; ras Proteins; Salicylates | 2022 |
Lipophilic modification of salirasib modulates the antiproliferative and antimigratory activity.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Farnesol; Salicylates | 2023 |